Under double-blind protocol, a controlled comparison was made between a new cephalosporin, cephacetrile, and cephalothin or cephaloridine. The patient's primary physician determined the indications for treatment, and the dosage was uniform for each route of administration. Infecting strains of staphylococci and Proteus mirabilis had a lower median inhibitory concentration for cephalothin than cephacetrile; the opposite was true for Escherichia coli and Klebsiella species. The average peak serum level 1 h after a dose of 2 g intravenously was 74.9 21 and 21.5 i 8.7 tsg/ml for cephacetrile and cephalothin, respectively; 6 h after the dose, the respective levels were 12.4 i 4.3 and 3.7 + 0.9 ,ug/ml. Renal clearances were similar and the plasma clearance was proportional to the serum levels. In the urine, the concentration of cephacetrile was three times higher than that of cephalothin. Based on a percentage of therapeutic potential, success in the treatment of infections with susceptible organisms was 42 and 44% for the two different drug regimens. Initial bacterial resistance was found in about one-fifth of infections, and concomitant therapy with other drugs was practiced in one-half of the treatment courses. Intravenous use of cephacetrile was discontinued prematurely more often than was use of cephalothin, suggesting less tolerance. Although there was no overt toxicity, more than 75% of patients on either regimen had some form of unwanted response to treatment, the most common being superinfection. From this limited but controlled experience, cephacetrile can be considered comparable to cephhlothin in antimicrobial treatment and overall side reactions.
The clinical introduction of new drugs of the same class as others already licensed and established in clinical practice poses problems in evaluation. One approach is to treat enough patients with the new drug to determine that it is effective as therapy for certain types of infections without regard for its relative worth. In the case of most new antibiotics, the effect of closely related drugs with similar in vitro activity would be difficult to differentiate in clinical practice. There may be exceptions if there are marked differences in the in vivo bioavailability of one of them or if a very large experience is gained which gives significance to minor clinical differences. Nontherapeutic differences, such as toxicity, pain, acceptability, and ease of use of the drugs, may be easier to ascertain. In all of these regards, the ideal investigation would be a double-blind study of In Table 3 , the results of treatment are shown according to the clinical conditions for which therapy was given. Some sizeable differences are apparent in the observed PTP, but owing to the small numbers of cases the differences have no statistical significance. In general, cephacetrile tended to be more effective against gramnegative bacilli, both in the urinary tract and in tissue infection. When all gram-negative bacillary infections were lumped except those from septicemia, where there was no test sample with cephalothin treatment, the PTP achieved was 58 versus 33% for cephacetrile and cephalothin, respectively. Against staphylococci, streptococci, and pneumococci, the sample was very small, owing to the elimination of cases obscured by concurrent treatment with other effective drugs. However, one cephacetrile failure occurred in a patient who died with a persistent beta-hemolytic streptococcal bacteremia.
Measurements of the peak and trough concentrations of cephacetrile and cephalothin in blood samples taken at specified times after a given dose from individual patients on the 3rd to 6th days of treatment are shown in Fig. 1 In Table 4 , the concentrations of each drug in the urine are given with data on the urinary excretion and renal clearance where measured. Cephacetrile attained concentrations in the urine that were three times greater than with the same dose of cephalothin. The extrarenal excretion (and degradation) of cephalothin was 2.7 times greater than for cephacetrile, whereas the renal clearance of the two was nearly the same. Higher urine concentrations of cephacetrile were obtained because of the higher plasma concentrations compared with cephalothin.
In Table 5 , the four categories of patients that were discerned after treatment are presented. Owing to the design, there were 31 courses of Superinfection of the urine with resistant organisms of Pseudomonas, Enterobacter, and Candida species occurred in three of seven patients treated with cephacetrile; herellea infection complicated therapy in one of two treated for pneumonia, and herellea and pseudomonas superinfected two of four patients treated for wound infections. Thus, in approximately one-half of patients treated for urinary, respiratory, or wound infections, cephacetrile was complicated by superinfection. This was of more overt consequence than among seven similar patients given cephalothin.
The different reactions recorded in Table 6 tended to occur in different patients; therefore, thrombophlebitis, superinfection, or a positive Patients who died (all non-drug related) and those given prophylactic treatment are excluded. The numbers in parentheses and brackets are, respectively, patients in whom the disease state could have caused the response and patients receiving concurrent treatment that could have been a factor.
Coombs test were adverse changes noted in 12 of 20 patients who survived therapy with cephacetrile and 3 of 10 given cephalothin. This is an overall incidence of 48% for these three conditions and not significantly different for the two drug regimens.
DISCUSSION
This investigation was planned to interfere as little as possible with the primary physicians' prescribing habits in the use of cephalosporin antibiotics and to compare, under these conditions, an investigational new drug with closely related established products. Cephalosporin treatment was prescribed for a broad irange of conditions, including prophylaxis, the treatment of simple urinary tract infections, and also severe or life-threatening infections in various body tissues. Both gram-negative and grampositive bacterial infections were included. Approximately one-third of the time, the specific etiology was not known before treatment was started, and commonly physicians combined cephalosporin with another antibiotic. These practices did not always provide good individual study cases, but the results provide a factual basis for the comparison of drugs regarding the methods of use, acceptability by patients and physicians, complications, and overall effectiveness. The study represents one of the few attempts to obtain controlled comparative information of this type. Although the number of patients in the series is modest, approximately 2,000 laboratory procedures were performed to follow their course and insure recognition or document the absence of toxicity associated with the investigational new drug. These bacteriological, chemical, and serological tests with the clinical observations required exemplify the large expense and effort involved in the attempt to provide an adequate basis to answer simple basic questions of relative efficacy and toxicity between antibiotics for use in man.
In vitro susceptibilities are among the best guidelines to therapy, especially the demonstration of resistance. As might have been predicted from in vitro tests, cephacetrile appeared clinically more active than cephalothin against strains of Klebsiella and Enterobacter. The finding of a few strains of Klebsiella that are highly resistant, almost surely owing to betalactamase production, is an ominous sign, because bacteria can transfer the ability to produce such enzymes to other bacteria as an R factor (2, 3). The in vitro effectiveness against E. coli and Proteus mirabilis was not confirmed in the clinical experience.
The observed average peak serum concentration of cephacetrile is in essential agreement with the observations of Nissenson et al. (9) when adjusted for dose and drug half-life. Hodges et al. (4) reported higher levels with an average serum concentration of 104 ,g/ml after 1.5 g of i.v. cephacetrile. It was known that cephalothin produces much lower plasma and urine concentrations of active drug than do other cephalosporins, primarily owing to its conversion to the desacetyl form (5, 6 ). This biologically less active metabolite averages about one-third of the dose of cephalothin but can be as high as 90% in some individuals. It is not known whether deacylation of cephalothin is the sole reason for the observed lower blood levels. It is curious that the difference is already observed in specimens taken 1 h after the dose, but the net loss of active drug from plasma between the 1st and 6th hours is proportionately the same (Fig. 2) . Thus, whatever the initial mechanism, the process is either discontinuous or not additive with the other modes of plasma clearance beyond the 1st hour. If the volume of distribution of cephalothin were significantly larger, it would be a partial explanation of the lower levels of cephalothin, but data available suggest this is not a major factor (5) . The renal clearance of cephacetrile is similar to that of cephalothin, and hepatic excretion of active drug is relatively low (1) .
The movement of drug into extravascular tissues and the secretions of various organs, the urine being the most obvious, may be of major importance in the treatment of specific conditions. In relating the pharmacological data to therapeutic results, cephacetrile, which attained higher urine concentrations, was more effective in urinary tract infections, but this trend was not significant. In the case of urinary tract infections, which comprised 41% of this experience, the presence of concentrations (in milligrams per milliliters) of drug in the urine represents a concentration overkill so enormous that major differences in microbial susceptibility and drug pharmacology would be overshadowed.
In addition to in vitro susceptibility and bioavailability of the drug, the influence of the host on the outcome of therapy owing to associated diseases was repeatedly observed In view of this and the pharmacological data which show plasma and urine levels of cephacetrile approximately three times greater than those of cephalothin after the same dose without any demonstrated therapeutic benefit, it would seem advantageous to consider use of a lower dose of cephacetrile. Serious gram-negative bacillary infections other than those of the urinary tract would remain as indications for high-dose intravenous administration. However, the limited effect of cephalosporins on Klebsiella species, their meager effect on Enterobacter bacilli, and the nil effect on organisms of the Pseudomonas and Serratia genera usually lead physicians to use other antibiotics in the treatment of these common gram-negative infections. Indications for combination therapy in this series were not always clear, but the data represent the practice of the primary physicians, which was to use aminoglycosides with cephalosporins in the treatment of approximately 30% of patients and some other antibiotic in another 20%. The benefit of such combinations over either drug alone against susceptible organisms has not been established.
Although the adverse reactions observed are not life-threatening or serious complications, they cannot be ignored. Thrombocytosis occurred in 11 of 30 patients and 9 of 27 patients reported by Hodges et al. (4) , which is more than expected from acute infections (8, 10) . Altogether, approximately 75% of patients treated with either of the drugs under study experienced some unwanted reaction. On this basis, and in order to minimize the risk of further transfer of resistance, restricted use of the cephalosporin antibiotics for prophylaxis is recommended.
This limited but controlled experience suggests that cephacetrile can be considered comparable to cephalothin as a therapeutic agent with the possible advantages of higher blood and urine levels and more flexibility in using intramuscular administration, but also perhaps more need to do so.
